Good morning, Armchair Army,
Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
Disclosure: Armchair Analyst Media Pty Ltd owns 2,000,000 EMD shares. EMD has engaged Armchair Analyst Media for investor awareness services. The article should be read with this relationship in mind.
This information is general in nature and does not constitute personal financial advice.
In the early hours of this morning, the FDA held its public hearing on psychedelics.
Participating in person…
Emyria (ASX: EMD).
(Yes, I was up at 2:30 am this morning to listen)
It was an interesting format; each speaker got 2 minutes to speak to the panel.
Either pitching an agenda (better safety, more training, etc.), raising a concern, or highlighting a lived experience.
When it came to Emyria’s turn, the submission wasn’t:
“Here is what we would like to see.”
It was:
“We have been building this for three years - here is what we have learned.
Emyria could point to real clinics, trained clinicians, treatment protocols, payer pathways and patient outcomes that they had delivered.
A big advertisement for Emyria, to a room full of industry stakeholders looking for answers on how to build this industry/
An interesting cross-section of people.
Academics.
Peak bodies.
Drug developers.
Multiple former service members and veterans’ organisations spoke about their own experiences, including people who had travelled to Mexico because they could not legally access treatment at home.
Clinicians were well represented too, including those who have provided care before.
(Either through clinical trials or ketamine clinics).
One line that stood out was:
“In psychedelic care, the physician is not just administering the treatment — they are part of the treatment.”
That is why training, accreditation, patient screening, and data collection matter so much.
(all areas that Emyria focuses on)
But Emyria's real value comes from the conversations around the hearing.
The fund managers.
The pharmaceutical companies.
The clinicians.
The groups now trying to work out how these drugs will actually reach patients if they are approved in America.
… and this morning we moved one more step closer.
BREAKING NEWS 🚨
This morning Definium (NASDAQ: DFTX) announced a third successful Phase 3 trial for psychedelic-assisted therapy.
The study tested a single dose of its LSD-based treatment in 245 patients with generalised anxiety disorder.
Result = primary endpoint met.
At Week 12, patients receiving the 100 µg dose improved by 9.8 points on the HAM-A anxiety scale, compared with 4.7 points for placebo.
But perhaps the most interesting result was what happened with functional unblinding.
91% of patients receiving 50 µg and 95% receiving 100 µg correctly guessed they were on the drug.
In other words… both groups basically knew they had received LSD.
Yet the 100 µg dose still performed better than the 50 µg dose.
That provides strong evidence of a dose-dependent pharmacological effect.
Definium plans to hold a pre-NDA meeting in Q4 2026, ahead of a planned New Drug Application in the first half of 2027.
The industry tailwinds are roaring.
The FDA is now publicly working through how to deliver these treatments.
Veterans are demanding access.
… And drug developers are producing positive Phase 3 data.
But every successful drug creates the same question:
Who is going to deliver it?
That is what the hearing was about. You can watch the full thing here, and listen to Emyria Chairman Greg Hutchinson speak from 1:20:00
Let’s dive in…
The Pulse Check
CurveBeam AI (ASX: CVB) receives FDA 510(k) clearance for its CT-based Bone Mineral Density technology. (CVB)
🪑 Well done, big win.
Amplia Therapeutics (ASX: ATX) finalises the study protocol for the Phase 2 clinical trial of its FAK inhibitor in combination with chemotherapy in advanced ovarian cancer. (ATX, held)
🪑 Milestone ticked.
Next steps: ethics approval, with the clinical trial set to start before the end of this year.
Mayne Pharma (ASX: MYX) signs a five-year exclusive licensing agreement in Australia for Blissel, a menopause hormone therapy. (MYX)
Argenica Therapeutics’ (ASX: AGN) preclinical concussion study has been selected for oral presentation at the International NeuroTrauma Congress. (AGN, held)
The FDA has begun its pre-approval inspection of EBR Systems (ASX: EBR) new manufacturing facility. (EBR)
Lumos Diagnostics (ASX: LDX) expands FebriDx® deployment to 215 live sites (up from 170) and 405 in evaluation across top US urgent care groups. (LDX)
🪑 Nice update.
Network rollout in full effect.
HeraMED (ASX: HMD) requests a trading halt pending a “material commercial deployment”. (HMD)
🪑 Interesting, wonder what this one could be 🤔
Epsilon Healthcare (ASX: EPN) Southport facility will serve as the exclusive global manufacturing partner for Helix’s cannabinoid nanoemulsion technology. (EPN)
Biotron Limited (ASX: BIT) announces the resignation of Dr Michelle Miller as CEO after 24 years. (BIT)
🪑 24 years is a very good innings.
REPORT: Start-ups and scientists raise alarm on government’s R&D changes. (AFR)
🪑 The lobbying has begun. Good to see.
See you all tomorrow,
The Armchair Analyst
What is an armchair pick?
An Armchair Pick is an invite-only spot I reserve for my highest-conviction investment ideas.
It's a paid arrangement, but to align myself, I only take my fee in shares - half escrowed for 6 months, half for 12.
It is general commentary only, not personal financial advice or a recommendation to buy, sell, or hold. Always see the disclosure at the top of the article and do your own research.
